Abstract
CEACAM1 adhesion molecule is broadly expressed, participates in pivotal cellular and immunological processes and is involved in cancer. Originally identified as a tumor suppressor, it is now known that in several cancers, including malignant melanoma, CEACAM1 expression correlates with tumor progression and poor survival. Here we review the findings connecting CEACAM1 to malignant melanoma, encompassing in-vitro, in-vivo and patients-derived data. A CEACAM1-mediated mechanism used by melanoma cells to evade immune attack is described in detail. Finally, the potential value of CEACAM1 as a melanoma biomarker and therapeutic target is being discussed.
Keywords: CEACAM1, melanoma, immunotherapy, cancer, biomarker, lymphocytes, target cells, extracellular signaling cues, malignant melanoma, immunogenic, integrin signaling, tumor infiltrating lymphocytes (TIL), human melanomaxenografted mice, RGD peptides, lung cancer
Current Topics in Medicinal Chemistry
Title: CEACAM1 in Malignant Melanoma: A Diagnostic and Therapeutic Target
Volume: 12 Issue: 1
Author(s): S. Sapoznik, R. Ortenberg, J.r Schachter and G. Markel
Affiliation:
Keywords: CEACAM1, melanoma, immunotherapy, cancer, biomarker, lymphocytes, target cells, extracellular signaling cues, malignant melanoma, immunogenic, integrin signaling, tumor infiltrating lymphocytes (TIL), human melanomaxenografted mice, RGD peptides, lung cancer
Abstract: CEACAM1 adhesion molecule is broadly expressed, participates in pivotal cellular and immunological processes and is involved in cancer. Originally identified as a tumor suppressor, it is now known that in several cancers, including malignant melanoma, CEACAM1 expression correlates with tumor progression and poor survival. Here we review the findings connecting CEACAM1 to malignant melanoma, encompassing in-vitro, in-vivo and patients-derived data. A CEACAM1-mediated mechanism used by melanoma cells to evade immune attack is described in detail. Finally, the potential value of CEACAM1 as a melanoma biomarker and therapeutic target is being discussed.
Export Options
About this article
Cite this article as:
Sapoznik S., Ortenberg R., Schachter J.r and Markel G., CEACAM1 in Malignant Melanoma: A Diagnostic and Therapeutic Target, Current Topics in Medicinal Chemistry 2012; 12 (1) . https://dx.doi.org/10.2174/156802612798919259
DOI https://dx.doi.org/10.2174/156802612798919259 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews ROS-scavenging and Anti-tyrosinase Properties of Crocetin on B16F10 Murine Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry Omega-3 Polyunsaturated Fatty Acids and Depression: A Review of the Evidence
Current Pharmaceutical Design Viral and Non-Viral Methods to Genetically Modify Dendritic Cells
Current Gene Therapy Analysis of Simple Sequence Repeats in Mammalian Cell Cycle Genes
Recent Advances in DNA & Gene Sequences (Discontinued) Treating Age-Related Macular Degeneration – Interaction of VEGF-Antagonists with their Target
Mini-Reviews in Medicinal Chemistry Role of FK506 Binding Proteins in Neurodegenerative Disorders
Current Medicinal Chemistry Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Inducers of Heme Oxygenase-1
Current Pharmaceutical Design New Approaches to Target the Androgen Receptor and STAT3 for Prostate Cancer Treatments
Mini-Reviews in Medicinal Chemistry Anticancer Effects of Ginsenoside Rh2: A Systematic Review
Current Molecular Pharmacology Cancer Immunotherapy: Battling Tumors with Gene Vaccines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents DNA Vaccines for Prostate Cancer
Current Cancer Therapy Reviews Genetic and Non-Genetic Determinants of the Pharmacological Activity of Statins
Current Drug Metabolism Thalidomide in Multiple Myeloma
Current Pharmaceutical Biotechnology Therapeutic Potential of Medicinal Plant Proteins: Present Status and Future Perspectives
Current Protein & Peptide Science Economics of Pharmacogenomics: Rethinking Beyond QALYs?
Current Pharmacogenomics and Personalized Medicine ABC Transporters, Bile Acids, and Inflammatory Stress in Liver Cancer
Current Pharmaceutical Biotechnology Hematological Malignancies and Pregnancy. A Brief Review
Reviews on Recent Clinical Trials Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
Current Cancer Drug Targets